Marrow Therapeutics Launches with $173M to Develop In Vivo Treatments for Blood Disorders
Trendline

Marrow Therapeutics Launches with $173M to Develop In Vivo Treatments for Blood Disorders

What's Happening? Marrow Therapeutics has officially launched with $173 million in combined Series A and B financing to advance its efforts in creating new treatments for severe blood disorders. The biotech secured $53 million in Series A funding, co-led by founder Scion Life Sciences and venBio, fo
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.